Impact of 5-HT₃ RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting

References

• Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol.17(9), 1441–1449 (2006).
   PubMed Web of Science ®Google Scholar
• Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst. Rev.1, CD006272 (2010).
   Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R et al. 99–04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer98(11), 2473–2482 (2003).
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol.14(10), 1570–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Kaushal J, Gupta MC, Kaushal V et al. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med. J.51(11), 871–875 (2010).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes JE, Blamble DA et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer116(24), 5659–5966 (2010).
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol.10(2), 115–124 (2009).
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol.15(2), 330–337 (2004).
   PubMed Web of Science ®Google Scholar
• Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259–25197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol.114(4), 860–866 (1995).
   PubMed Web of Science ®Google Scholar
• Wong EH, Clark R, Leung E et al. The interaction of RS 25259–25197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol.114(4), 851–859 (1995).
   PubMed Web of Science ®Google Scholar
• Li Y, Wu X, Rojas C et al. Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat nodose ganglia. Presented at: 51st American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg.107(2), 469–478 (2008).
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol.626(2–3), 193–199 (2010).
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol.19(6), 1759–1767 (2001).
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol.21(22), 4105–4111 (2003).
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled Phase III clinical trials. Eur. J. Cancer40(3), 403–410 (2004).
   PubMed Web of Science ®Google Scholar
• Gralla RJ, de Wit R, Herrstedt J et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer104(4), 864–868 (2005).
   PubMed Web of Science ®Google Scholar
• Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support. Oncol.4(8), 403–408 (2006).
   PubMedGoogle Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer112(9), 2080–2087 (2008).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J. Clin. Oncol.21(22), 4112–4119 (2003).
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al.; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer97(12), 3090–3098 (2003).
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support. Care Cancer18(4), 423–431 (2010).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol.17(6), 1000–1006 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, Phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci.101(11), 2455–2461 (2010).
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer94(11), 3032–3041 (2002).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol.18(19), 3409–3422 (2000).
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology; Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update. J. Clin. Oncol.24(18), 2932–2947 (2006); Erratum in: J. Clin. Oncol.24(33), 5341–5342 (2006).
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol.21(Suppl. 5), v232–v243 (2010).
   Google Scholar
• Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer17(5), 589–594 (2009).
   PubMed Web of Science ®Google Scholar
• Longo F, Mansueto G, Lapadula V et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer DOI: 10.1007/s00520-010-0930-x (2010) (Epub ahead of print).
   PubMedGoogle Scholar